InformationInformation Center

R&D Progress of Recombinant Anti- CTLA-4 Human Monoclonal Antibody Injection

R&D Progress of Recombinant Anti- CTLA-4 Human Monoclonal Antibody Injection

On May 14th, 2018, Hualan Genetic Engineering Co. Ltd, the subsidiary of Hualan Biological Engineering, Inc. ( hereinafter referred to as " Genetic Company" ) received the new drug application acceptance notice of " Recombinant Anti- CTLA-4 Human Monoclonal Antibody Injection" issued by China Food and Drug Administration.

Hualan | Hualan Biological
This application for clinical study of "Recombinant Anti- CTLA-4 All-Human Monoclonal Antibody Injection" was accepted, which showed that the "Recombinant Anti- CTLA-4 All-Human Monoclonal Antibody Injection" had completed pre-clinical study and entered the registration application procedure. According to the relevant laws and regulations of national drug registration, "Recombinant Anti- CTLA-4 All-Human Monoclonal Antibody Injection" will be reviewed by CFDA after getting the clinical research application acceptance. Then, the drug Clinical Trial Permission will be issued after the review and approval.

Hualan | Hualan Biological


TAG:  Recombinant Anti- CTLA-4 Human Monoclonal Antibody Injection, Hualan Bio, CFDA